Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Release Tacrolimus (FK506E) vs Standard Tacrolimus in Kidney Transplantation
NCT00189839Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2004
- Primary completion
- Dec 2006
- Modality
- RNA-Targeting Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Time to and incidence of biopsy-proven acute rejections at 12 months. Started Aug 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00189839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189839.